JP2023522038A5 - - Google Patents

Info

Publication number
JP2023522038A5
JP2023522038A5 JP2022562711A JP2022562711A JP2023522038A5 JP 2023522038 A5 JP2023522038 A5 JP 2023522038A5 JP 2022562711 A JP2022562711 A JP 2022562711A JP 2022562711 A JP2022562711 A JP 2022562711A JP 2023522038 A5 JP2023522038 A5 JP 2023522038A5
Authority
JP
Japan
Prior art keywords
hinge
ccr
item
car
hinge region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022562711A
Other languages
English (en)
Japanese (ja)
Other versions
JP7802684B2 (ja
JP2023522038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/027648 external-priority patent/WO2021211948A1/en
Publication of JP2023522038A publication Critical patent/JP2023522038A/ja
Publication of JP2023522038A5 publication Critical patent/JP2023522038A5/ja
Priority to JP2025106623A priority Critical patent/JP2025129196A/ja
Application granted granted Critical
Publication of JP7802684B2 publication Critical patent/JP7802684B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022562711A 2020-04-17 2021-04-16 修飾ccrポリペプチド及びその使用 Active JP7802684B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025106623A JP2025129196A (ja) 2020-04-17 2025-06-24 修飾ccrポリペプチド及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011494P 2020-04-17 2020-04-17
US63/011,494 2020-04-17
PCT/US2021/027648 WO2021211948A1 (en) 2020-04-17 2021-04-16 Modified ccr polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025106623A Division JP2025129196A (ja) 2020-04-17 2025-06-24 修飾ccrポリペプチド及びその使用

Publications (3)

Publication Number Publication Date
JP2023522038A JP2023522038A (ja) 2023-05-26
JP2023522038A5 true JP2023522038A5 (cg-RX-API-DMAC7.html) 2024-04-25
JP7802684B2 JP7802684B2 (ja) 2026-01-20

Family

ID=78084154

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562711A Active JP7802684B2 (ja) 2020-04-17 2021-04-16 修飾ccrポリペプチド及びその使用
JP2025106623A Pending JP2025129196A (ja) 2020-04-17 2025-06-24 修飾ccrポリペプチド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025106623A Pending JP2025129196A (ja) 2020-04-17 2025-06-24 修飾ccrポリペプチド及びその使用

Country Status (8)

Country Link
US (1) US20240261404A1 (cg-RX-API-DMAC7.html)
EP (1) EP4136119A4 (cg-RX-API-DMAC7.html)
JP (2) JP7802684B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230005147A (cg-RX-API-DMAC7.html)
CN (1) CN115397864A (cg-RX-API-DMAC7.html)
AU (1) AU2021255702A1 (cg-RX-API-DMAC7.html)
CA (1) CA3180329A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021211948A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020379735A1 (en) 2019-11-05 2022-05-26 Regeneron Pharmaceuticals, Inc. N-terminal SCFV multispecific binding molecules
WO2022094314A1 (en) * 2020-10-30 2022-05-05 The University Of North Carolina At Chapel Hill Dual targeting chimeric antigen receptors
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes
EP4504768A2 (en) * 2022-05-17 2025-02-12 Arsenal Biosciences, Inc. Systems of engineered receptors targeting psma and ca9
USD1066799S1 (en) * 2022-08-12 2025-03-11 Kiss Nail Products, Inc. Applicator for artificial eyelashes
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5104853A (en) * 1984-12-11 1992-04-14 California Biotechnology Inc. Alveolar surfactant proteins having cys to ser mutations
EP3115373B1 (en) * 2010-09-08 2019-08-28 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
GB201513540D0 (en) * 2015-07-31 2015-09-16 King S College London Therapeutic agents
EP3336107A1 (en) * 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
AU2019315440B2 (en) * 2018-07-30 2025-03-13 Angeles Therapeutics, Inc. Improving the efficacy and safety of adoptive cellular therapies
EP3632460A1 (en) * 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
KR20210072797A (ko) * 2018-10-05 2021-06-17 세인트 안나 킨더크렙스포르슝 키메라 항원 수용체(car) 그룹
EP3632461A1 (en) * 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
CN113474012B (zh) * 2019-01-25 2023-09-08 湖南远泰生物技术有限公司 Epcam抗体和epcam-car-t细胞
MX2021015495A (es) * 2019-06-14 2022-04-18 2Seventy Bio Inc Composiciones y métodos para tratar cáncer.

Similar Documents

Publication Publication Date Title
JP7487112B2 (ja) Cd19指向性キメラ抗原受容体および免疫療法におけるその使用
AU2021307614B2 (en) Engineered immune cell for allotransplantation
JP7767502B2 (ja) Nk阻害性分子を発現する遺伝子改変免疫細胞とその使用
JP2022537159A5 (cg-RX-API-DMAC7.html)
US20200038443A1 (en) Multi-function and multi-targeting car system and methods for use thereof
EP4219693A1 (en) Chimeric antigen receptor targeting cd7 and use thereof
CA3140393A1 (en) Combinations of engineered natural killer cells and engineered t cells for immunotherapy
JP2021514631A5 (cg-RX-API-DMAC7.html)
JP2020500530A5 (cg-RX-API-DMAC7.html)
JP2017504601A5 (cg-RX-API-DMAC7.html)
CN114015656A (zh) 用于同种异体移植的工程化免疫细胞
EP4194472A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
JP2022513460A5 (cg-RX-API-DMAC7.html)
JP2015527070A5 (cg-RX-API-DMAC7.html)
CA3164666A1 (en) Bcma-directed cellular immunotherapy compositions and methods
JP2024534471A5 (cg-RX-API-DMAC7.html)
JP2024525727A5 (cg-RX-API-DMAC7.html)
WO2023207388A1 (zh) 一种cd7基因被敲除的工程化免疫细胞及其用途
CN117187185A (zh) 一种工程化免疫细胞及其用途
CN117004604A (zh) 一种ciita基因被敲除的工程化免疫细胞及其用途
Weiner et al. Antibodies and cancer therapy: versatile platforms for cancer immunotherapy
JP2024531910A5 (cg-RX-API-DMAC7.html)
EP4663762A2 (en) Immune rejection-resistant engineered cell
US20210079111A1 (en) Cd19-cd20 bispecific and dual passway car-t and methods for use thereof
CN117430712A (zh) 靶向cxcr6的嵌合抗原受体及其用途